D
ilated cardiomyopathy (DCM) is one of the main causes of heart failure and the leading indication for cardiac transplantation worldwide. 1 DCM is defined as left ventricular enlargement and systolic dysfunction in the absence of coronary artery disease, hypertension, valvular disease, or congenital heart disease sufficient to explain the observed myocardial abnormality. 2 DCM is commonly classified into familial or nonfamilial disease, where the nonfamilial disease is more likely to be because of nongenetic causes such as tachycardia, alcohol or drug abuse, inflammation, infection, and nutritional deficiencies. 2 Familial DCM is a genetically heterogeneous disease caused by variants with variable expressivity and penetrance. Variants in >50 genes have been associated with DCM, most encoding cytoskeletal, sarcomere, Z-band, nuclear membrane, and intercalated disc proteins. 3 In the majority of cases, DCM is inherited in an autosomal dominant manner although other modes of inheritance have been described such as autosomal recessive, X-linked recessive, and mitochondrial inheritance. 4, 5 Cardiovascular screening in relatives of DCM probands has revealed familial disease in 20% to 50% of cases, depending on the definition of the disease. 6 However, the true prevalence of familial DCM is not known.
Familial DCM can be accompanied by other cardiac defects or extracardiac manifestations, such as muscular dystrophies. 7 Conduction system abnormalities and arrhythmias that can be life-threatening may precede structural changes and their correlation with myocardial abnormalities may not be obvious. [8] [9] [10] Unfortunately, causative variants have only been found in less than half of familial cases. 11 Thus, there is still much to be learned about the genetic causes of DCM and the penetrance and expressivity of causative variants, 12 all of great importance for risk prediction and management of individuals and families with DCM. 13 The aim of this study was to search for variants causing DCM in Iceland and to establish the relationship between genotypes and phenotypic diversity of the disease. In contrast to prior research on the genetics of familial DCM, which has mostly included isolated families and tested-specific genes, we performed a population-based genome-wide study based on whole genome sequencing. This approach allows for a more accurate assessment of the relationship between the genotype and the phenotype because the carrier status was not preferentially ascertained for DCM cases and provides a better estimation of the penetrance and expressivity of each variant.
METHODS
The data, analytic methods, and study materials will/have been made available to other researchers for purposes of reproducing the results or replicating the procedure.
14 The Icelandic population whole genome sequencing data has been deposited at the European Variant Archive under accession code PRJEB8636. The authors declare that the data supporting the findings of this study are available within this article, its Data Supplement and on request. The analytical methods are available in the Data Supplement.
The study was approved by the Icelandic Data Protection Authority and the National Bioethics Committee of Iceland (VSNb2015030013/03.01, VSNb2015030022/03.01). All patients and controls who donated DNA samples signed informed consent. Personal identifiers of the patient data and biological samples were encrypted with a third party system monitored by the Data Protection Authority. The study complies with the Declaration of Helsinki. The article adheres to the American Heart Association Journals' implementation of the Transparency and Openness Promotion Guidelines.
RESULTS

Variants in FLNC and NKX2-5 Cause DCM in Iceland
We tested ≈32.5 million sequence variants for association with DCM in 424 Icelandic cases and 337 689 population controls (Table I in −12 ). Variants in NKX2-5, a cardiac transcription factor gene, are known to cause congenital heart defects and conduction disorders and were recently associated with DCM in 2 candidate gene resequencing studies. 15, 16 The other DCM variant is a frameshift variant p.Phe1626Serfs*40 in FLNC carried by 1 in 3600 Icelanders (allele frequency, 0.014%; OR=79.8; P=2.1×10 −10 ; Table 1 ; Figures I and II in the Data Supplement). Missense and loss-of-function variants in FLNC cause myofibrillar myopathy, muscular dystrophy characterized by adult-onset muscle weakness. 17 Affected individuals are at risk of developing cardiomyopathy and cardiac conduction abnormalities. 18 More recently, variants in FLNC were reported to cause cardiomyopathy in the absence of skeletal muscle defects. [19] [20] [21] The population of Iceland is roughly 330 000 and its genealogy is well documented. We observed that the carriers of the NKX2-5 variant cluster in a 6-generation family and share an ancestor born in 1865 (Figure 1 ). We identified 23 heterozygous carriers of the NKX2-5 variant in our data set, 17 with chip-genotype information (of which 7 were whole genome sequenced) and 6 obligate carriers. Six carriers have electronic medical record (EMR) diagnosis of cardiomyopathy. The carriers of the FLNC variant make up a larger family cluster, having a common ancestor born in 1595 ( Figure III in the Data Supplement). We identified 50 heterozygous carriers of this variant, 39 with chip-type genotype information (of which 8 were whole genome sequenced) and 11 obligate carriers. Four had EMR diagnosis of cardiomyopathy. As expected, based on the rarity of the variants, we found no homozygote carrier of either variant. Neither variant is present outside of Iceland and they are neither listed in The Genome Aggregation Database (n=138 632) nor in Ensembl. 22, 23 We did not observe these variants in the >15 000 Icelanders sequenced outside of the families. To confirm the existence of the variants and to validate the imputation, we performed Sanger sequencing of predicted carriers followed by reimputation. Both variants associate more strongly with cardiomyopathy after reimputation (Table II in the Data Supplement).
We tested both variants for association with 14 cardiac conditions and related traits ( Table 2 ). Both variants associate with ventricular tachycardia, sudden cardiac death, and heart failure. In addition, the NKX2-5 variant associates with high degree atrioventricular block and atrial septal defect (ASD) and the FLNC variant associates with risk of coronary artery disease (P<0.05/14=0.0036). No other sequence variant associates genome-wide significantly with DCM in our material after adjusting for these 2. Using our set of whole genome sequenced DCM cases, we screened for variants reported to be pathogenic by ClinVar. 24 An in-frame deletion, p.Arg14del in PLN, is carried by 1 in 6250 Icelanders. Two out of 42 identified carriers had an EMR diagnosis of DCM (OR=17.7; P=1.8×10 −5 ). The variant showed similar association with the risk of heart failure (OR=8.6; P=1.0×10 −5 ). Six DCM cases carried the MYB-PC3 splice variant c.927-2A>G known to cause HCM. 25 Whole genome sequenced carriers of the NKX2-5 and the FLNC variants do not have any other variant in candidate genes that might be causative. We note that individuals who have not been whole genome sequenced and do not carry these variants may carry other diseasecausing variants not identified in this study.
Clinical Characteristics of Carriers of the NKX2-5 Variant
Of the 23 carriers of the NKX2-5 variant (Figure 1 ), 12 died at the mean age of 63 (range: 25-95 years) and 11 were alive at the mean age of 42 (range: 20-65 years). The following description pertains to 13 carriers (8 living) for whom medical records were available for review (Table 3) . Eight had been diagnosed with cardiomyopathy at the mean age of 51 (range: 24-63 years), 6 with DCM and 2 with cardiomyopathy of unknown type. The majority of cases were diagnosed as a familial disease. The largest individual left ventricular end-diastolic dimension measured in DCM hearts of NKX2-5 variant carriers ranged from 61 to 83 mm by echocardiography and the ejection fraction (EF) ranged from 15% to 45%. Both carriers with cardiomyopathy of unspecified type had one available echocardiogram showing left ventricular end-diastolic dimension of 52 and 59 mm and EF 45% and >50%, respectively. Two carriers had arrhythmias but not overt cardiomyopathy at ages 38 and 52. One of them had supraventricular tachycardia and the other high-grade atrioventricular block and ventricular tachycardia. Three variant carriers with cardiomyopathy had a variety of risk factors before diagnosis including alcohol use, drug abuse, aortic regurgitation, atrial fibrillation, and coronary artery disease. Three of the 13 carriers had not been diagnosed with heart disease at the time of medical record review. They were younger (age 26-45 years) than the mean age at diagnosis of cardiomyopathy in this family (51 years).
Conduction disease and arrhythmias are common among the NKX2-5 variant carriers. The most common are supraventricular tachycardia, atrioventricular block, bundle branch block, atrial fibrillation, and ventricular tachycardia/fibrillation. All 8 carriers with cardiomyopathy had conduction disease; 5 were diagnosed before and 2 at the time of diagnosis of the cardiomyopathy and 1 had an uncertain temporal relationship with the diagnosis of DCM. Four of 7 carriers were initially diagnosed with first-degree atrioventricular block, that progressed to high-grade atrioventricular block requiring pacemaker implantation, a noteworthy finding in light of the commonly benign nature of first-degree atrioventricular block. 26 Four carriers suffered sudden cardiac death after diagnosis of cardiomyopathy. In total, 6 had pacemakers implanted and 3 an implantable cardioverter-defibrillator for serious arrhythmias. Congenital heart defects were also common in this family, found in 4 of the 13 carriers. Two had ASD, 1 had ventricular septal defect, and 1 had a pericardial cyst.
Of the 10 carriers for which medical records were not available, 7 were deceased of which 3 had died before the age of 50. One of those had cardiomyopathy according to EMR diagnostic code data. One other individual was middle-aged at time of the study with EMR diagnosis of complete atrioventricular block and 2 were young adults with no EMR diagnoses.
Clinical Characteristics of Carriers of the FLNC Variant
The p.Phe1626Serfs*40 variant in FLNC is less penetrant for cardiomyopathy than the NKX2-5 variant. We identified 50 p.Phe1626Serfs*40 carriers, 10 of whom had died at a mean age of 66 years (range: 40-87). The following description applies to 38 carriers with available medical records, noting that completeness and depth of information varied (Table 3) . Nine were diagnosed with cardiomyopathy, 8 with DCM, and 1 with HCM. Eight of the cases were classified as idiopathic, one was thought to be because of myocarditis at time of diagnosis, and none was recognized as familial.
The 9 carriers with cardiomyopathy were diagnosed at a mean age of 48 years (range: 40-58). The largest measured left ventricular end-diastolic dimension ranged from 62 to 82 mm and EF ranged from 15% to 50%. The HCM case was diagnosed at autopsy after sudden cardiac death. Two carriers had a heart transplant. Two had history of alcohol abuse, 1 also used anabolic steroids before the diagnosis of DCM. One individual with DCM experienced myocardial infarction before the diagnosis of DCM. Of the 29 carriers who had not been diagnosed with cardiomyopathy at the time of this study, 14 were younger than 48 years, the mean age at diagnosis of cardiomyopathy.
Three carriers suffered sudden cardiac death at the ages of 40 to 79. Two were diagnosed with DCM before the event and one was diagnosed with HCM at autopsy. Twelve carriers had conduction disease and arrhythmias. The most common types were supraventricular tachycardia, atrioventricular block, atrial fibrillation, or ventricular tachycardia. Seven of those had overt cardiomyopathy, but in contrast to carriers of the NKX2-5 variant, the temporal relationship between conduction disease/arrhythmia and diagnosis of cardiomyopathy was less certain.
Variants in FLNC cause myofibrillar myopathy, a disease characterized by slowly progressing muscle weakness in adulthood. 17 None of the 38 FLNC p.Phe1626Serfs*40 variant carriers with medical records available for review was diagnosed with myofibrillar or any other type of myopathy. Two had problems that could be because of myopathy. One had DCM and weakness of extremities after the age of 70. The other did not have DCM but described weakness and cramps in extremities before the age of 50.
Association With ECG Parameters
Both variants associate with ECG parameters (Figure 2) . The NKX2-5 variant prolongs the PR segment and the duration of the QRS complex and affects the T wave amplitude and area. The strongest association was with the PR-interval (lead II, P=3.7×10 −6 , effect=1.54 (Figure 2 ; Tables III through VI in the Data Supplement). One of those, rs2277923[C] (minor allele frequency=28.6%) in NKX2-5, associating most notably with the PR segment (lead V 4 , P=1.1×10 −17 , effect=−0.06 SD), was recently reported to be a potential contributor to the risk of sporadic ASD in Chinese Yunnan population. 27 In our data, rs2277923 does not associate with ASD but associates with risk of atrial fibrillation (P=3.1×10 −6 , OR=0.92) and tags rs6882776, reported to associate with heart rate. 28 In our data, rs227792 associates with heart rate (P=0.0061, effect=−0.018), but not in the absence of atrial fibrillation (P=0.31, effect=−0.008).
DISCUSSION
We performed a genome-wide association study based on whole genome sequencing to search for variants that associate with DCM in Iceland. We found a missense variant in NKX2-5 and a frameshift variant in FLNC that cause familial DCM and sudden cardiac death. The penetrance of serious heart disease among carriers of the NKX2-5 variant is high and higher than that of the FLNC variant. Among carriers >40 years of age who were alive in 1980, 71% (10/14) of the NKX2-5 carriers and 25% (9/36) of the FLNC carriers have been diagnosed with serious heart disease. We note that these estimates may be biased downwards because of incomplete phenotypic information.
NKX2-5 encodes a homeobox-containing transcription factor that is critical during embryonic cardiac development and for proper cardiac conduction and contraction postnatally. 29, 30 The variant reported here, p.Phe145Leu, is in the homeodomain (AA 138-197), an evolutionary conserved domain, and the phenylalanine at position 145 contributes with 10 other amino acids to the hydrophobic core responsible for the tertiary structure of the homeodomain. 31 The variant is predicted by in silico tools to have a detrimental effect on protein function (Sorting Tolerant From Intolerant: deleterious; PolyPhen-2: probably damaging). Biochemical analyses of 8 missense variants in the homeodomain in humans revealed marked reduction in DNA binding affinity. 34 Furthermore, a study of the crystal structure of NKX2-5 shows that variants in the hydrophobic core destabilize the whole homeodomain and have more effects on protein function than other homeodomain variants. 31 Given that Phe145 is evolutionary conserved and has a role in the hydrophobic core, p. Phe145Leu is likely to result in an unstable homeodomain and thus reduced DNA binding affinity of NKX2-5.
32,33
Variants in NKX2-5 are known to cause a diverse cardiac phenotype and variation in expressivity. 35 The most common phenotypes are progressive atrioventricular block, eventually requiring pacemaker implantation, and congenital heart defects, especially secundum ASDs. 36 Recently, NKX2-5 variants were found to associate with adult-onset DCM 15, 16 and ventricular arrhythmias. 37 We show that p.Phe145Leu in NKX2-5 causes a severe type of adult-onset familial DCM with very high penetrance and a notable risk of sudden cardiac death. The 3 variant carriers evaluated without heart disease were too young at the time of the study to be expected to have developed disease.
The associated findings of congenital heart disease, most commonly ASD, and progressive conduction disorder, are typical of NKX2-5 variants. In most p.Phe145Leu carriers, conduction disorder was the first sign of heart disease, and in some, was recognized over a decade before the onset of cardiomyopathy or arrhythmia.
FLNC encodes filamin C, a large actin-crosslinking protein expressed in striated muscles. The actin-binding domain is at the amino-terminus followed by 24 immunoglobulin-like domains. Filamin C anchors major protein complexes at the sarcolemma, Z-discs, and intercalated discs in cardiomyocytes to the actin cytoskeleton and provides a scaffold for a variety of cytoplasmic signaling proteins. 38, 39 A previous study suggests that filamin C has an important role in maintenance of the structural integrity of striated muscles against mechanical stress. 39 The variant we report, p.Phe1626Serfs*40, is a truncating variant located in Ig-like domain 15.
Several variants in FLNC have been associated with 2 distinct types of myopathy. Variants in FLNC Ig-like domains 7, 10, 22, and 24 have been associated with myofibrillar myopathy with protein aggregation of mutant filamin C and various other proteins. 17, [40] [41] [42] Myofibrillar myopathy is characterized by progressive proximal muscle weakness and, in some cases, nonspecific cardiomyopathy and respiratory failure in late disease. 40 Variants in an actin-binding domain and Iglike domain 15, were associated with a distal myopathy phenotype lacking pathological features such as protein aggregation. 43, 44 Since 2014, variants in FLNC have been associated with isolated cardiomyopathies, both DCM, HCM, and restrictive cardiomyopathy. [19] [20] [21] 45 Variants associated with HCM and restrictive cardiomyopathy were mostly missense variants and histopathology of cardiac muscle showed protein aggregates. 20, 21 More recently, truncating variants in FLNC were associated with an overlapping phenotype of dilated and left-dominant arrhythmogenic cardiomyopathies complicated by premature sudden death. No evidence was found of skeletal myopathy, suggesting an exclusive cardiac phenotype. 45 Of the 38 Icelandic p.Phe1626Serfs*40 carriers with available medical records, 9 were diagnosed with cardiomyopathy but none with myofibrillar or any other type of myopathy. Whether the variant results in an exclusive cardiac phenotype or confers risk of milder forms of myopathy remains to be determined.
It is notable that none of the 9 FLNC DCM cases was recognized as familial, highlighting the fact that DCM cases thought to be sporadic may indeed be familial, warranting a detailed family history and consideration of cardiovascular screening of family members. A combination of relatively low penetrance and incomplete family history probably explains why the familial basis was not identified in these cases. Other reasons for lack of familial history or transmission include small family size and de novo variants.
We have shown that very rare variants in NKX2-5 and FLNC cause adult-onset familial DCM in Iceland with associated risk of heart failure and sudden cardiac death. The NKX2-5 variant is also associated with high degree atrioventricular block and with ASD, characteristic for this gene. It is established that early and presymptomatic intervention can delay progression of cardiomyopathy and we would agree with others who have suggested that surveillance and early treatment may be beneficial for carriers of pathogenic variants in NKX2-5 and FLNC. 46 For the Icelandic variants, prophylactic use of an implantable cardioverter-defibrillator once cardiomyopathy has developed, or even earlier, may be considered based on the high risk of sudden cardiac death.
